Biomedical subjects

Angelo Marronaro

Publications and source records attributed to Angelo Marronaro.

6 recordsLinked to original sources

PubMed2004

Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.

OBJECTIVE: To determine whether prostate specific antigen (PSA) level can usefully predict or exclude bladder outlet obstruction (BOO), in men with lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: A cohort of men from 1996 to 1999 who had LUTS caused by BPH was evaluated by serum PSA and pressure-flow urodynamic studies, and a blinded comparison made. The settings were teaching hospitals in London, UK and L'Aquila, Italy. Men (302) were referred by primary-care practitioners with LUTS and a PSA of < 10 ng/mL. Regression analysis was used to predict the extent of BOO, and create likelihood ratios and predictive values for BOO according to the PSA value. RESULTS: PSA was significantly associated with BOO (P < 0.001; r2 0.07), with significant likelihood ratios altering the probability of BOO. If the PSA was > 4 ng/mL, mild or definite BOO was likely (89%), whereas if the PSA was <2 ng/mL, there was about a one-third chance each of no, mild and definite BOO. CONCLUSION: High PSA levels in patients with LUTS are significantly associated with BOO; low PSA levels mean that definite BOO is unlikely.

Aged↗

PubMed2003

Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

PURPOSE: To investigate the effects of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') on the cellular proliferation of androgen-sensitive and androgen-independent human prostatic cancer cell lines and primary cultures in vitro. EXPERIMENTAL DESIGN: In this study, we investigated the effects of the quinazoline ZD1839, a potent, selective EGFR-TKI, on the EGFR autophosphorylation and cellular proliferation of androgen-sensitive (ND1, LNCaP, and ALVA-31) and androgen-independent (PC3, DU145, and TSU-Pr1) human prostatic cancer cell lines and 20 primary cultures derived from human prostatic cancer tissue. RESULTS: EGFR was present and phosphorylated in all cell lines tested. ZD1839 reduced EGFR autophosphorylation in intact cell lines with IC(50)s of 0.46-0.97 microM, and inhibited cellular proliferation with IC(50)s of 0.37-1.03 microM. Constitutive EGFR autophosphorylation was low in primary cell cultures, but addition of EGF (50 ng/ml) caused marked EGFR autophosphorylation; cellular proliferation in the presence of EGF was inhibited by ZD1839 with a mean IC(50) of 0.45 microM. At doses >1 microM, ZD1839 induced apoptosis in both androgen-dependent and androgen-independent PCa cell lines. CONCLUSION. Our experiments suggest that EGFR-TKIs such as ZD1839 may have potential in blocking the growth and progression of human prostatic cancers even in early phases of the disease.

Antineoplastic Agents↗

PubMed2002

[Percutaneous treatment of varicocele: considerations and our experience].

UNLABELLED: Due to its high incidence and its affecting male infertility, varicocele is an important disease. Consequently, it is essential to choose the best treatment. MATERIALS AND METHODS: Since 1999 to 2000, 75 patients affected by varicocele (mean age 25 years) underwent percutaneous retrograde sclerotherapy through a right transfemoral approach. Pre-operative tests included physical examination, sperm analysis and colour Doppler sonography. According to Dubin and Amelar classification, 59% of patients were affected by Grade 3 varicocele. According to Hirsh classification, grade III-IV varicocele was diagnosed with colour Doppler sonography in 77.3% of patients. Mean operative time was 30 minutes with only 5 minutes of exposure to radiation. All patients were followed-up with colour Doppler ultrasound and sperm analysis 1, 4 and 12 months after the treatment. RESULTS: In 6 of 75 patients (8%) sclerotherapy was unsuccessful because it was not possible to catheterize the spermatic vein. No significant complications were observed pre and post-operatively. 3 patients complained of mild testicular pain and 1 case had a transient hydrocele. The patients were dismissed during the next 24 hours after the procedure. During follow-up, physical examination was unremarkable in all patients, while occlusion of spermatic veins showed by Doppler ultrasound at 4 and 12 months was achieved in 94% of patients. CONCLUSIONS: Retrograde sclerotherapy through trans-femoral approach is a safe and effective treatment. In our opinion it should be considered as the treatment of choice, especially if we consider the costs, hospitalization and complications of conventional surgery and laparoscopy.

Adolescent↗

PubMed2002

[Ultrasonographic assessment of bladder volume].

INTRODUCTION: The aim of this study is to evaluate intra and inter-observatory variability in the sonography measurement of bladder volume. MATERIALS AND METHODS: We have evaluated 138 patients (128 men and 10 women) affected by lower urinary tract symptoms with a mean age of 64 years (range 36-75) between December 2000 and June 2001. Sonography measurement of bladder volume was obtained at the end of a pressure/flow study with the double lumen catheter in situ. Measurement of bladder volume was performed by the same operator in 113 patients by calculating the transverse, longitudinal and anterior-posterior diameter; each measurement was repeated three times. In the remaining 25 patients examination was performed by three different operators for every patients, with a single evaluation for each operator. The real volume was measured by emptying the bladder using the urethral catheter. RESULTS: The real bladder volume in the intra and inter-observatory group was 240 +/- 130 and 145 +/- 97, respectively. First, second and third measurement in the intra-observatory group were 229 +/- 113, 231 +/- 112, 234 +/- 127, respectively. On the other hand, first, second and third measurement in the inter-observatory group were 131 +/- 73, 129 +/- 66, 143 +/- 94, respectively. CONCLUSIONS: Looking at our results, it is clear that there is no significant difference between every single measurement in the intra and inter-observatory group. In addition, the estimation of bladder volume by ultrasound was quite similar to the real volume. We conclude that ultrasound is a precise, non invasive and highly reproducible technique to calculate the bladder volume.

Adult↗

PubMed2002

[Transrectal prostatic biopsy with "end-fire" endovaginal probe].

OBJECTIVE: Sextant ultrasound-guided biopsy is still the standard way for the diagnosis of prostate cancer, although there have been several modifications. We report our experience using a 7.5 MHz endovaginal "end-fire" probe in patients undergoing prostate biopsy because of clinical findings suggestive of prostate cancer (abnormal digital rectal examination and/or elevated prostate specific antigen). MATERIALS AND METHODS: Since June 1999 to December 2001, we performed 262 ultrasound-guided transrectal 18G core biopsies with a 7.5 MHz endovaginal "end-fire" probe, using different schemes according to the presence or not of suspicious areas on ultrasound (a modified sextant biopsies plus two cores from the transitional zone with multiple cores from and around suspected lesions in case of abnormal findings on ultrasound). RESULTS: We obtained a detection rate of about 44%. Complications were mild: 5 cases (1.9%) of urosepsis and 4 cases (1.5%) of urinary retention. Both haematuria and rectal bleeding were not significant. CONCLUSIONS: The endovaginal "end-fire" probe allows us to obtain core biopsies in both longitudinal and transverse view. This means an optimal sampling of the prostate gland, in particular a better and safer sampling of transitional zone avoiding the prostatic urethra and the choice of the best plane in order to sample more peripheral zone and its lateral aspects. Furthermore, with the "end-fire" probe it is quite simple to obtain cores biopsies from every portion of the prostate gland and, consequently, it is possible to make an accurate staging of the disease prior to surgery.

Aged↗

PubMedDate not supplied

Bicalutamide dose-dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures.

OBJECTIVE: Androgen antagonists inhibit prostatic cell proliferation in normal and pathological conditions and are useful antitumor agents in prostatic carcinoma (PCa). Bicalutamide (BCLT) is a well-known non-steroidal antiandrogenic agent able to interfere with androgen receptor (AR). We tested the efficacy of BCLT in inhibiting proliferation of human PCa cell lines and of primary cultures from biopsies of PCa patients. MATERIALS AND METHODS: Human prostatic carcinoma cell lines (PC3, DU145, LNCaP ALVA 31 and ND1) and short-term primary tissue cultures from PCa patients were treated with BCLT. Cell proliferation and orange acridine and ethidium bromide fluorescence staining studies were performed. RESULTS: BCLT was able to inhibit, significantly and dose-dependently, cell proliferation in AR-positive human PCa cell lines and in 10 cases of primary cultures with Gleason grades 4 to 8. Its action appears to be mainly apoptotic in AR-positive cells and cytotoxic in AR-negative cells. CONCLUSION: BCLT, which inhibits growth in both human PCa cell lines and PCa primary cultures from patients with medium and low-grade tumors, deserves attention as a potential widely effective antiandrogenic monotherapy in prostatic carcinoma. However, its efficacy in AR-negative cells requires further research.

Acridine Orange↗